Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen.

Abstract

OBJECTIVES:

The aim of this retrospective study was to determine the response to a single injection of pegylated asparaginase ('pegaspargase') and to assess the tolerability and outcome of prolonged incorporation of pegaspargase into a modified COP (cyclophosphamide, vincristine, prednisolone) regimen in pegaspargase sensitive cats.

METHODS:

Fifty-six client-owned cats with confirmed macroscopic high-grade lymphoma at any anatomical site were included. Treatment was commenced with a single pegaspargase injection. Cats showing an objective response were eligible to continue therapy with pegaspargase incorporated into a modified COP protocol and had their survival analysed using the Kaplan-Meier method and log-rank test.

RESULTS:

Objective response to pegaspargase was reported in 46 cats (82%), including 21 (38%) complete and 25 (44%) partial responses. Thirty-four responders continued therapy with pegaspargase-COP as the first-line treatment. Of these, 31 cats (92%) achieved complete remission with a median duration of the first remission (disease-free survival [DFS]) of 816 days. The median overall survival time (OST) for all 34 cats treated with pegaspargase-COP was 181 days. Response to the initial pegaspargase injection before COP initiation was significantly associated with DFS (P = 0.04) and OST (P = 0.001). Median DFS/OST for cats with complete response to initial pegaspargase injection was significantly longer compared with those with partial remission (>1273 days/>2066 days vs 77 days/108 days, respectively). Cats with gastric lymphoma showed a significantly longer survival (OST 854 days, 1- and 2-year survival rate 57.1%) compared with cats with intestinal lymphoma (OST 102 days, 1-year survival rate 0%). The pegaspargase-COP protocol was generally well tolerated, but two deaths were likely attributable to treatment-related toxicity during the maintenance phase. Importantly, none of the cats experienced hypersensitivity, despite multiple repeated treatments with pegaspargase.

CONCLUSION AND RELEVANCE:

Pegaspargase is an effective agent for feline lymphoma. Its incorporation into a COP chemotherapy protocol may confer a survival benefit, especially in cats with complete response to pegaspargase. Treatment is generally well tolerated, but careful monitoring is recommended. Further studies are required to assess the benefits of pegaspargase as monotherapy or as part of different multi-agent chemotherapy regimens.

• Authors: Adriana Krupa, Johan de Vos, Lynn Van Eetvelde, Erik Teske
• Journal: Journal of feline medicine and surgery (J Feline Med Surg) Vol. 24 Issue 8 Pg. e203-e213 (08 2022) ISSN: 1532-2750 [Electronic] England
• PMID: 35748790 (Publication Type: Journal Article)

Chemical References

• Polyethylene Glycols
• pegaspargase
• Cyclophosphamide
• Asparaginase

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Asparaginase (adverse effects, therapeutic use)
• Cat Diseases (etiology)
• Cats
• Cyclophosphamide (adverse effects)
• Lymphoma (veterinary)
• Lymphoma, Non-Hodgkin (drug therapy, etiology, veterinary)
• Polyethylene Glycols
• Retrospective Studies